SSY Group gains approval for timolol maleate eye drops

SSY Group Limited (HKEX: 2005) announced that it has secured approvals for drug production and registration of its 0.3ml Timolol Maleate Eye Drops in unit dose packaging (0.5% and 0.25%) from the National Medical Products Administration of China. The "Product" is considered to be a type 3 chemical drug and has passed consistency evaluation. This marks the first such approval for PRC entities and represents the Group’s second type of ophthalmic preparation medicines. The company anticipates further approvals for other ophthalmic preparations and expects a new sales channel for this product series by the end of 2025. The product is designed to reduce intraocular pressure, primarily for open-angle glaucoma, and is also effective for other types of glaucoma and ocular hypertension. The announcement is intended to keep shareholders informed of the latest business developments.